TMCnet News
Castle Biosciences to Present at the Canaccord Genuity 2016 Medical Technology & Diagnostics ForumCastle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced that Derek Maetzold, President and CEO, will be presenting at the Canaccord Genuity 2016 Medical Technology & Diagnostics Forum today, Thursday, November 17th, 2016 at 1:40 p.m. EST in New York.
About Castle Biosciences DecisionDx-Melanoma, DecisionDx-UM and DecisionDx-PRAME are the trademarks of Castle Biosciences, Inc. Any other trademarks are the property of their respective owners.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161117005648/en/ |